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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 31 prioritisation (May 2017), 10 drugs were filteredout of 302 identified and were sent to 
prioritisation. Of these, 4 drugs were ranked as ‘highly relevant’ by the expert panel, 5 as ‘relevant’ 
and 1 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
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1. Comparison of adjuvant gemcitabine and capecitabine (Xeloda
®) with gemcitabine 
monotherapy in patients with resected pancreatic cancer 
Not 
relevant 
2. First-line ceritinib (Zykadia
®) versus platinum-based chemotherapy in advanced ALK-
rearranged non-small-cell lung cancer  
Highly 
relevant 
3. Dabrafenib (Tafinlar
®) plus trametinib in patients with previously treated BRAFV600E-
mutant metastatic non-small cell lung cancer Relevant 
4. Pembrolizumab (Keytruda®) as second-line therapy for advanced urothelial carcinoma Highly 
relevant 
5. Pembrolizumab (Keytruda
®) for platinum- and cetuximab-refractory head and neck 
cancer 
Relevant 
6. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma Relevant 
7. Idelalisib (Zydelig
®) or placebo in combination with bendamustine and rituximab in 
patients with relapsed or refractory chronic lymphocytic leukaemia 
Highly 
relevant 
8. Nivolumab (Opdivo®) for previously treated unresectable metastatic anal cancer Relevant 
9. 
Mucosa-associated lymphoid tissue lymphoma: improved event-Free and progression-
free survival with rituximab (MabThera®) plus chlorambucil versus either chlorambucil or 
rituximab monotherapy 
Relevant 
10. 
Bortezomib (Velcade®) with lenalidomide and dexamethasone versus lenalidomide and 
dexamethasone alone in patients with newly diagnosed myeloma without intent for 
immediate autologous stem-cell transplant 
Highly 
relevant 

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1 Lung cancer 
1.1 First-line ceritinib (Zykadia®) versus platinum-based 
chemotherapy in advanced ALK-rearranged non-small-cell 
lung cancer  
 
Overview 
Drug Description small molecule, ATP-competitive inhibitor of the tyrosine kinase  
anaplastic lymphoma kinase (ALK) 
Patient Indication ceritinib for untreated patients with stage IIIB/IV ALK-rearranged non-
squamous non-small-cell lung cancer (NSCLC) 
Incidence in 
Austria 
4,716 newly diagnosed per year (2014), 56.9/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase II NCT01828099 until 06/2018 
Approval 
status for 
this 
indication 
EMA - 
FDA 02/2017: priority review for ALK-positive metastatic NSCLC in the first line 
Approval 
status for 
other 
indications 
EMA 05/2015: for advanced ALK-positive NSCLC that has been treated before with Xalkori (crizotinib) 
FDA 04/2014: for late-stage (metastatic) NSCLC after progression or intolerance to 
crizotinib 
Costs 
ZYKADIA 
1 treatment cycle: 750 mg ceritinib per day for 21-days; ex-factory price of 
150 mg per 150 pieces = € 5,355.30  € 3,748.71 per treatment cycle 
 Published articles (PubMed): 1.1.1
Lancet (2017), published online March 12, 2017 (Soria et al.) “First-line ceritinib versus platinum-
based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a 
randomised, open-label, phase 3 study” 
Background 
The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-
small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus 
platinum-based chemotherapy in these patients. 
 
Methods 
This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged 
non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned 
via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy 
([cisplatin 75 mg/m² or carboplatin AUC 5–6 plus pemetrexed 500 mg/m²] every 3 weeks for four 
cycles followed by maintenance pemetrexed); randomisation was stratified by World Health 
Organization performance status (0 vs 1–2), previous neoadjuvant or adjuvant chemotherapy, and 
presence of brain metastases as per investigator’s assessment at screening. Investigators and 
patients were not masked to treatment assignment. The primary endpoint was blinded independent 
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review committee assessed progression-free survival, based on all randomly assigned patients (the 
full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were 
done based on the safety set, which included all patients who received at least one dose of study 
drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. 
 
Findings 
Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) 
or chemotherapy (n=187). Median progression-free survival (as assessed by blinded independent 
review committee) was 16.6 months (95% CI 12.6–27.2) in the ceritinib group and 8.1 months (5.8–
11.1) in the chemotherapy group (hazard ratio 0.55 [95% CI 0.42–0.73]; p<0.00001). The most 
common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting 
(125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and 
nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the 
chemotherapy group. 
 
Interpretation 
First-line ceritinib showed a statistically significant and clinically meaningful improvement in 
progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC. 
2 Urothelial carcinoma 
2.1 Pembrolizumab (Keytruda®) as second-line therapy for 
advanced urothelial carcinoma 
 
Overview 
Drug Description human programmed death receptor-1 (PD-1)-blocking antibody 
Patient Indication pembrolizumab for patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy 
Incidence in 
Austria 
1,427 newly diagnosed per year (2014), 17.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02256436 - until 01/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
 
 
 
 
Approval 
status for 
other 
indications 
 
 
 
 
 
 
 
 
 
 
 
EMA 
07/2015: as monotherapy for advanced (unresectable or metastatic) 
melanoma in adults 
 
07/2016: for locally advanced or metastatic non-small cell lung carcinoma 
(NSCLC) in adultswhose tumours express PD-L1 and who have received at 
least one prior chemotherapy regimen. Patients with EGFR or ALK positive 
tumour mutations should also have received approved therapy for these 
mutations prior to receiving pembrolizumab 
 
01/2017: as monotherapy for metastatic NSCLC in the first line in 
adultswhose tumours express PD-L1 with a ≥50% tumour proportion score 
(TPS) with no EGFR or ALK positive tumour mutations 
 
FDA 
09/2014: for unresectable or metastatic melanoma, after disease progression 
following ipilimumab and if positive BRAF V600 mutation  
10/2016: 
• for metastatic NSCLC in patients whose tumours have high PD-L1 
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Approval 
status for 
other 
indications 
 
 
expression (Tumour Proportion Score [TPS] greater than or equal to 
50%) as determined by an FDA-approved test, with no EGFR or ALK 
genomic tumour aberrations, and no prior systemic chemotherapy 
treatment for metastatic NSCLC 
• for metastatic NSCLC in patients whose tumours express PD-L1 (TPS 
greater than or equal to 1%) as determined by an FDA-approved test, 
with disease progression on or after platinum-containing chemotherapy. 
Patients with EGFR or ALK genomic tumour aberrations should have 
disease progression on FDA-approved therapy for these aberrations 
prior to receiving pembrolizumab 
08/2016: for recurrent or metastatic head and neck squamous cell carcinoma 
with disease progression on or after platinum-containing chemotherapy 
 
10/2016: for metastatic non-small cell carcinoma in the first line 
Costs 
KEYTRUDA 
1 treatment cycle: 200 mg pembrolizumab every three weeks; ex-factory price 
of 25 mg/ml 4ml = € 3,428,-  € 6,856,- per treatment cycle 
 Published articles (PubMed): 2.1.1
NEJM (2017), published online February 17, (Bellmunt et al.) “Pembrolizumab as Second-Line 
Therapy for Advanced Urothelial Carcinoma” 
Background 
Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have 
a poor prognosis and limited treatment options. 
 
Methods 
In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced 
urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive 
pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against 
programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator’s choice of 
chemotherapy with paclitaxel, docetaxel, or vinflunine. The co-primary end points were overall survival 
and progression-free survival, which were assessed among all patients and among patients who had a 
tumour PD-1 ligand (PD-L1) combined positive score (the percentage of PD-L1–expressing tumour 
and infiltrating immune cells relative to the total number of tumour cells) of 10% or more. 
 
Results 
The median overall survival in the total population was 10.3 months (95% confidence interval [CI], 8.0 
to 11.8) in the pembrolizumab group, as compared with 7.4 months (95% CI, 6.1 to 8.3) in the 
chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91; P = 0.002). The median 
overall survival among patients who had a tumour PD-L1 combined positive score of 10% or more was 
8.0 months (95% CI, 5.0 to 12.3) in the pembrolizumab group, as compared with 5.2 months (95% CI, 
4.0 to 7.4) in the chemotherapy group (hazard ratio, 0.57; 95% CI, 0.37 to 0.88; P = 0.005). There was 
no significant between-group difference in the duration of progression-free survival in the total 
population (hazard ratio for death or disease progression, 0.98; 95% CI, 0.81 to 1.19; P = 0.42) or 
among patients who had a tumour PD-L1 combined positive score of 10% or more (hazard ratio, 0.89; 
95% CI, 0.61 to 1.28; P = 0.24). Fewer treatment-related adverse events of any grade were reported 
in the pembrolizumab group than in the chemotherapy group (60.9% vs. 90.2%); there were also fewer 
events of grade 3, 4, or 5 severity reported in the pembrolizumab group than in the chemotherapy 
group (15.0% vs. 49.4%). 
 
Conclusion 
Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) 
and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy 
for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 
ClinicalTrials.gov number, NCT02256436.) 
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3 Leukaemia 
3.1 Idelalisib (Zydelig®) or placebo in combination with 
bendamustine and rituximab in patients with relapsed or 
refractory chronic lymphocytic leukaemia 
 
Overview 
Drug Description an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase 
Patient Indication idelalisib in combination with bendamustine and rituximab in patients with 
relapsed or refractory chronic lymphocytic leukaemia 
Incidence in 
Austria 
936 newly diagnosed per year (2014), 11.3/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase II NCT01569295 until 12/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
02/2016 (+ofatumumab) & 09/2014 (+rituximab): in combination with an anti‑
CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of 
adult patients with chronic lymphocytic leukaemia (CLL): 
 
• who have received at least one prior therapy, or 
• as first line treatment in  the presence of 17p deletion or TP53 
mutation in patients who are not eligible for any other therapies  
 
09/2014: as monotherapy for the treatment of adult patients with follicular 
lymphoma (FL) that is refractory to two prior lines of treatment  
FDA 
07/2014: 
• for relapsed chronic lymphocytic leukaemia (CLL), in combination 
with rituximab, in patients for whom rituximab alone would be 
considered appropriate therapy due to other co-morbidities 
• for relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients 
who have received at least two prior systemic therapies 
• for relapsed small lymphocytic lymphoma (SLL) in patients who have 
received at least two prior systemic therapies 
Costs 
ZYDELIG 
1 treatment cycle: twice-daily oral idelalisib (150 mg); ex-factory price of 60 
pieces 150 mg = € 3,700,-  € 3,453,- per treatment cycle 
LEVACT 
1 treatment cycle: 70 mg/m² intravenously on days 1 and 2 (assuming an 
average body surface area of 1.75 m²); ex-factory price of 500 mg =  
€ 1,505.98,-  € 735.2,- per treatment cycle 
MabThera 
Cycle 1: 375 mg/m² on day 1 (assuming an average body surface area of 
1.75 m²); ex-factory price of 500 mg = € 1,516.43,-  € 1,990.3,- per 
treatment cycle  
Cycles 2–6: 500 mg/m² on day 1 (assuming an average body surface area of 
1.75 m²); ex-factory price of 500 mg =  € 1,516.43,-  € 2,653.8,- per 
treatment cycle 
Total costs for combination therapy for the first treatment cycle: € 6,178.5,-. 
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 Published articles (PubMed): 3.1.1
Lancet 2017 March, 18(3):297-311 (Zelenetz et al.) “Idelalisib or placebo in combination with 
bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: 
interim results from a phase 3, randomised, double-blind, placebo-controlled trial” 
Background 
Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or 
refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant 
outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class 
targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. 
 
Methods 
For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with 
relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable 
lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous 
therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response 
system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m2 
intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m2 on day 1 of cycle 1, and 
500 mg/m2 on day 1 of cycles 2–6) in addition to either twice-daily oral idelalisib (150 mg) or placebo 
until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by 
high-risk features (IGHV, del[17p], or TP53 mutation) and refractory versus relapsed disease. The 
primary endpoint was progression-free survival assessed by an independent review committee in the 
intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number 
NCT01569295. 
 
Findings 
Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the 
idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7–18), 
median progression-free survival was 20.8 months (95% CI 16.6–26.4) in the idelalisib group and 11.1 
months (8.9–11.1) in the placebo group (hazard ratio [HR] 0.33, 95% CI 0.25–0.44; p<0.0001). The 
most frequent grade 3 or worse adverse events in the idelalisib group were neutropenia (124 [60%] of 
207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia 
(99 [47%] of 209) and thrombocytopenia (27 [13%]). An increased risk of infection was reported in the 
idelalisib group compared with the placebo group (grade ≥3 infections and infestations: 80 [39%] of 
207 vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and 
pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo 
group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) 
patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections 
in the idelalisib group and three from infections in the placebo group. 
 
Interpretation 
Idelalisib in combination with bendamustine plus rituximab improved progression-free survival 
compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic 
lymphocytic leukaemia. However, careful attention needs to be paid to management of serious 
adverse events and infections associated with this regimen during treatment selection. 
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4 Multiple myeloma 
4.1 Bortezomib (Velcade®) with lenalidomide and 
dexamethasone versus lenalidomide and dexamethasone 
alone in patients with newly diagnosed myeloma without 
intent for immediate autologous stem-cell transplant 
Overview 
Drug Description a first-in-class proteasome inhibitor 
Patient Indication 
bortezomib with lenalidomide and dexamethasone for untreated multiple 
myeloma who were not planned for immediate 
autologous stem-cell transplant 
Incidence in 
Austria 
382 newly diagnosed per year (2014), 4.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02136134 - until 03/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
12/2013: as monotherapy or in combination with pegylated liposomal 
doxorubicin or dexamethasone is indicated for the treatment of adult 
patients with progressive multiple myeloma who have received at least 1 
prior therapy and who have already undergone or are unsuitable for 
haematopoietic stem cell transplantation. 
08/2008: in combination with melphalan and prednisone is indicated for 
the treatment of adult patients with previously untreated multiple myeloma 
who are not eligible for high dose chemotherapy with haematopoietic stem 
cell transplantation. 
06/2013: in combination with dexamethasone, or with dexamethasone and 
thalidomide, is indicated for the induction treatment of adult patients with 
previously untreated multiple myeloma who are eligible for high dose 
chemotherapy with haematopoietic stem cell transplantation. 
01/2015: in combination with rituximab, cyclophosphamide, doxorubicin 
and prednisone is indicated for the treatment of adult patients with 
previously untreated mantle cell lymphoma who are unsuitable for 
haematopoietic stem cell transplantation. 
FDA 
06/2003: for the treatment of patients with multiple myeloma 
12/2006: for the treatment of patients with mantle cell lymphoma who have 
received at least one prior therapy. 
Costs  
VELCADE 
Dexamethasone: in one treatment cycle a dosis of 20 mg was 
administered 8 times  total of 160 mg; 100 mg  € 28.70 and for 160 
mg costs of € 45.92 would incur for 1 treatment cycle 
Bortezomib: 1.3 mg/square meter body surface administered 
(subcutaneously) 4 times per treatment cycle; 3.5 mg  € 1,218.95 
assuming a body surface of 1.70 m2, 2.21 mg (€ 769.68) are needed per 
administration and for 1 treatment cycle costs of €3,078.7 would incur 
Lenalidomide: 1 cycle: 25 mg daily on days 1–14; 21 pieces  € 6,696.10 
and for 1 treatment cycle (14 pieces) € 4,464.1 would incur  
Total costs of € 7,588.72 for 1 treatment cycle (21-days) of combination 
treatment would incur 
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 Published articles (PubMed): 4.1.1
Lancet (2016) published online December 22, (Durie et al.): “Bortezomib with lenalidomide and 
dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed 
myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, 
open-label, phase 3 trial” 
Background 
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed 
myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and 
dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed 
to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve 
progression-free survival and provide better response rates in patients with previously untreated 
multiple myeloma, who were not planned for immediate autologous stem-cell transplant. 
 
Methods 
In this randomised, open-label, phase 3 trial, we recruited patients with newly diagnosed multiple 
myeloma aged 18 years and older from participating Southwest Oncology Group (SWOG) and 
National Clinical Trial Network (NCTN) institutions (both inpatient and outpatient settings). Key 
inclusion criteria were presence of CRAB (C=calcium elevation; R=renal impairment; A=anaemia; 
B=bone involvement) criteria with measurable disease (measured by assessment of free light chains), 
Eastern Cooperative Oncology Group (ECOG) performance status of 0–3, haemoglobin concentration 
9 g/dL or higher, absolute neutrophil count 1 × 103 cells per mm3 or higher, and a platelet count of 
80 000/mm3 or higher. We randomly assigned (1:1) patients to receive either an initial treatment of 
bortezomib with lenalidomide and dexamethasone (VRd group) or lenalidomide and dexamethasone 
alone (Rd group). Randomisation was stratified based on International Staging System stage (I, II, or 
III) and intent to transplant (yes vs no). The VRd regimen was given as eight 21-day cycles. 
Bortezomib was given at 1·3 mg/m2 intravenously on days 1, 4, 8, and 11, combined with oral 
lenalidomide 25 mg daily on days 1–14 plus oral dexamethasone 20 mg daily on days 1, 2, 4, 5, 8, 9, 
11, and 12. The Rd regimen was given as six 28-day cycles. The standard Rd regimen consisted of 25 
mg oral lenalidomide once a day for days 1–21 plus 40 mg oral dexamethasone once a day on days 1, 
8, 15, and 22. The primary endpoint was progression-free survival using a pre-specified one-sided 
stratified log rank test at a significance level of 0·02. Analyses were intention to treat. This trial is 
registered with ClinicalTrials.gov, number NCT00644228. 
 
Findings 
Between April, 2008, and February, 2012, we randomly assigned 525 patients at 139 participating 
institutions (264 to VRd and 261 to Rd). In the randomly assigned patients, 21 patients in the VRd 
group and 31 in the Rd group were deemed ineligible based mainly on missing, insufficient, or early or 
late baseline laboratory data. Median progression-free survival was significantly improved in the VRd 
group (43 months vs 30 months in the Rd group; stratified hazard ratio [HR] 0.712, 96% CI 0.56–
0.906; one-sided p value 0.0018). The median overall survival was also significantly improved in the 
VRd group (75 months vs 64 months in the Rd group, HR 0.709, 95% CI 0.524–0.959; two-sided p 
value 0.025). The rates of overall response (partial response or better) were 82% (176/216) in the VRd 
group and 72% (153/214) in the Rd group, and 16% (34/216) and 8% (18/214) of patients who were 
assessable for response in these respective groups had a complete response or better. Adverse 
events of grade 3 or higher were reported in 198 (82%) of 241 patients in the VRd group and 169 
(75%) of 226 patients in the Rd group; 55 (23%) and 22 (10%) patients discontinued induction 
treatment because of adverse events, respectively. There were no treatment-related deaths in the Rd 
group, and two in the VRd group. 
 
Interpretation 
In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and 
dexamethasone resulted in significantly improved progression-free and overall survival and had an 
acceptable risk-benefit profile. 
